BCLSI
SYRS

Bain Capital Life Sciences Investors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,750,151
Closed -$632K – 25
2024
Q4 		$632K Hold
2,750,151
– – 0.07% 26
2024
Q3 		$5.91M Buy
2,750,151
+343
+0% +$1.23K 0.62% 19
2024
Q2 		$14.2M Hold
2,749,808
– – 1.56% 12
2024
Q1 		$14.7M Hold
2,749,808
– – 1.18% 17
2023
Q4 		$21.4M Buy
2,749,808
+625,114
+29% +$2.14M 2.05% 12
2023
Q3 		$8.39M Hold
2,124,694
– – 0.94% 22
2023
Q2 		$6.69M Hold
2,124,694
– – 0.69% 26
2023
Q1 		$5.67M Hold
2,124,694
– – 0.71% 27
2022
Q4 		$7.63M Buy
2,124,694
+1,042,290
+96% +$4.52M 0.85% 25
2022
Q3 		$6.97M Buy
1,082,404
+455,962
+73% +$3.7M 0.83% 24
2022
Q2 		$6.03M Hold
626,442
– – 0.71% 26
2022
Q1 		$7.46M Hold
626,442
– – 0.72% 25
2021
Q4 		$20.4M Buy
626,442
+47,938
+8% +$1.94M 1.62% 17
2021
Q3 		$25.9M Hold
578,504
– – 1.6% 15
2021
Q2 		$31.5M Hold
578,504
– – 2.07% 12
2021
Q1 		$43.3M Hold
578,504
– – 2.45% 11
2020
Q4 		$62.8M Buy
+578,504
New +$52.8M 3.94% 7

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Bain Capital Life Sciences Investors's SYRS Position: Q1 2025 in Review

Bain Capital Life Sciences Investors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 2,750,151 shares — an estimated $632K sold.

Bain Capital Life Sciences Investors first reported a position in SYRS in Q4 2020 and held it in 17 quarters. The position peaked at $62.8M in Q4 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Bain Capital Life Sciences Investors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 2,750,151 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $632K.
  • Bain Capital Life Sciences Investors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 17 quarters.
  • Bain Capital Life Sciences Investors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $62.8M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2025, filed 15 May 2025.